Carousel Previous Carousel Next. Jump to Page. Search inside document. Hydraulic destruction on bond microleakage Which intra-canal medicament causes protein coagulation: a. Sealants least effective on a primary molars b 2nd primary molar c … In primary tooth for restoration before putting the filling u put a base b calcium hydroxide c varnish While u were preparing a canal u did a ledge, then u used EDTA with the file, this may lead to a perforation of the strip b … Pt with renal transplantation came with white elevated lesion on tongue no history of smoking or tobacco chewing diagnosis is : a-candidiasis b-iatrogenic lesion c-hyperkeratosis d-stomatitis PDL Incisor The x ray show scattered radioopaque line in the mandible jaw the diagnosis will be: a- Paget disease b- Garres syndrome c- Fibrous dysplasia d- Osteosarcoma Weeping canal: a Calcium hydroxide.
None of the above Documents Similar To Questions. Osama Bakheet. Younus Shaik. S S Saad Saad. Zana Hussein. Mrunal Doiphode. Adeel Ahmad. Junaid Ramzan. Sumi Ali. Priya Sargunan. Anup Lal Rajbahak. Anonymous XPsvSYddrw. Mohammed Qasim Al-Watary. Jose Roldan. Khalid Iqbal. Angelique Vikram Goel. Milton Morales. Kareem Shawa. Basant Shams. Gujapaneni Ravi Kumar. More From smile4Dr. Tissue Engineering of Temporomandibular Joint Cartilage.
Popular in Pulp Tooth. Matias Soto Parra. Muhammed Thanseeh. Shruti Sood. Hayley Welsh. Carlos San Martin. Rehema Mulewa. Nallely Mondragon. Silvia Solis. Raniya Zain. Jainath Jain. Ahmed Febri Hertama 'Sinosuke'. Subhajit Saha. Mohamed Aita. Anonymous s0HyPIcd. Volume Article Contents Introduction. Prevention of no-reflow. Pharmacological treatment of no-reflow. Why do drugs fail in the treatment of no-reflow?
Exploitation of endogenous protective mechanisms. A clinical approach to no-reflow: prevention is better than treatment. No-reflow: again prevention is better than treatment. Oxford Academic. Rajesh K. Filippo Crea. Adrian P. Revision received:. Select Format Select format. Permissions Icon Permissions. Open in new tab Download slide. Figure 2. Table 1 Main studies focused on the prevention of mechanisms of no-reflow.
Preventive measures. Study design. Number of patients. Timing of intervention. Primary endpoints. Main results. Pre-during-post- PCI Infarct size and extent of microvascular obstruction Significant reduction in infarct size and microvascular obstruction by i. Pre-PCI Cardiovascular death or rehospitalization for congestive heart failure Improved myocardial reperfusion and fewer deaths and less cardiac failure after 2. Open in new tab.
Figure 3. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Google Scholar Crossref. Search ADS. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.
The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia.
Google Scholar PubMed. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis.
Effect of chronic aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes.
The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction.
A randomized, double-blind, placebo-controlled clinical trial. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction J-WIND : two randomised trials. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.
Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. Randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction DIGAMI study : effects on mortality at 1 year. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction.
High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction AMISTAD-II. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.
Frequency of slow coronary flow following successful stent implantation and effect of nitroprusside. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation.
Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study.
Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Preconditioning the myocardium: from cellular physiology to clinical cardiology. All and only full-text papers in English were considered. Results Study selection Participants The search retrieved studies. Characteristics of included studies The characteristics of the 11 studies meeting the inclusion criteria are summarized in Table 1.
Downloaded from ueg. Flow-chart diagram detailing the paper selection process. The overall RR was 0. In the considered comparable. Primary outcomes The meta-analyses of the two primary outcomes inves- tigated mortality and overall complications. The overall relative risk RR was 0. Table 1. Comparison of baseline patient characteristics No. Table 3. Comparison of tumour location, cancer stage, neoadjuvant therapy, and protective ileostomy Mean distance No. Table 4.
Quality assessment of the included non-randomized controlled studies based on the Newcastle-Ottawa scale Selections Comparability Outcome assessment 1 2 3 4 5 6 7 Score Leung et al. Outcome assessment: 6, Clearly defined outcome of interest if yes, one point for information ascertained by medical records or interview; no points if this information was not reported ; 7, Follow-up equal between the two groups if yes, one point; no points if follow-up not reported.
Conversion rates ranged between 1. In the RCT studies, reported conver- sion rates showed a time trend, which was not apparent 0. The overall incidence of intra-operative injuries, as reported in six studies, was 1. Event rate plotted on and open surgery patients; the overall RR was 1. Forest plot for day mortality.
CI, confidence interval; RR, relative risk; W, weight of single study. Forest plot for overall day morbidity. Forest plot for day surgical complications. Forest plot for day medical complications. Forest plot for mean operative time. CI, confidence interval; MD, mean difference; W, weight of single study. Forest plot for mean blood loss. Forest plot for incidence of intra-operative injuries.
Forest plot for bowel movement recovery. On the other hand, wound complications, as Anastomotic leakages, as reported in eight studies, reported in 10 studies, were described for 6. Forest plot for food intake recovery. Forest plot for incidence of blood transfusion. The overall RR was 1.
Forest plot for incidence of abdominal abscesses. Forest plot for incidence of wound complications. Forest plot for incidence of anastomotic leakage. Forest plot for incidence of re-intervention. Forest plot for length of hospital stay.
This was cancer plays a major role. For mid and low rectal can- considered important in order to obtain results as cers, total mesorectal excision remains the main-stay of homogeneous as possible. Although a meta-analysis therapy. The feasibility of laparoscopic resection of of only RCT studies might be considered preferable, rectal cancer has been demonstrated for many years the risk of bias analysis and the heterogeneity test when performed by expert laparoscopists, but while showed that extending the inclusion criteria to pro- the laparoscopic approach in colon cancer has been spective non-randomized matched series would have proved to be safe and feasible with equivalent long- allowed a consistent level of evidence to be maintained.
Where data were available, stage of although only including intra-peritoneal lesions. We restricted the beginning of the analysis to assessing risk of bias and the Newcastle-Ottawa scale the year in order to include studies performed with was interestingly high. The main preted with caution as the present analysis shows cer- result of the meta-analysis was that the incidence of tain limitations.
Furthermore the mortality lacked important data with regard to secondary analysis showed a trend in favour of laparoscopy, outcomes. In fact, in References the past few years, concern has been expressed about 1.
0コメント